83 related articles for article (PubMed ID: 8961802)
1. Two-step immunological approaches for imaging and therapy.
Rosebrough SF
Q J Nucl Med; 1996 Sep; 40(3):234-51. PubMed ID: 8961802
[TBL] [Abstract][Full Text] [Related]
2. Pretargeted radioimmunotherapy of cancer: progress step by step.
Boerman OC; van Schaijk FG; Oyen WJ; Corstens FH
J Nucl Med; 2003 Mar; 44(3):400-11. PubMed ID: 12621007
[TBL] [Abstract][Full Text] [Related]
3. Pretargeted radioimmunotherapy.
Meredith RF; Buchsbaum DJ
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S57-9. PubMed ID: 16979441
[TBL] [Abstract][Full Text] [Related]
4. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods.
Sharkey RM; Karacay H; Cardillo TM; Chang CH; McBride WJ; Rossi EA; Horak ID; Goldenberg DM
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7109s-7121s. PubMed ID: 16203810
[TBL] [Abstract][Full Text] [Related]
5. Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization.
Casalini P; Luison E; Ménard S; Colnaghi MI; Paganelli G; Canevari S
J Nucl Med; 1997 Sep; 38(9):1378-81. PubMed ID: 9293791
[TBL] [Abstract][Full Text] [Related]
6. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system.
Goodwin DA; Meares CF; Osen M
J Nucl Med; 1998 Oct; 39(10):1813-8. PubMed ID: 9776294
[TBL] [Abstract][Full Text] [Related]
7. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
Gautherot E; Le Doussal JM; Bouhou J; Manetti C; Martin M; Rouvier E; Barbet J
J Nucl Med; 1998 Nov; 39(11):1937-43. PubMed ID: 9829586
[TBL] [Abstract][Full Text] [Related]
8. Improved tumor targeting by combined use of two antitenascin antibodies.
Petronzelli F; Pelliccia A; Anastasi AM; D'Alessio V; Albertoni C; Rosi A; Leoni B; De Angelis C; Paganelli G; Palombo G; Dani M; Carminati P; De Santis R
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7137s-7145s. PubMed ID: 16203813
[TBL] [Abstract][Full Text] [Related]
9. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Reagent development.
Karacay H; Sharkey RM; Govindan SV; McBride WJ; Goldenberg DM; Hansen HJ; Griffiths GL
Bioconjug Chem; 1997; 8(4):585-94. PubMed ID: 9258459
[TBL] [Abstract][Full Text] [Related]
10. Tumor pretargeting for radioimmunodetection and radioimmunotherapy.
Zhu H; Jain RK; Baxter LT
J Nucl Med; 1998 Jan; 39(1):65-76. PubMed ID: 9443740
[TBL] [Abstract][Full Text] [Related]
11. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model.
Sharkey RM; Karacay H; Griffiths GL; Behr TM; Blumenthal RD; Mattes MJ; Hansen HJ; Goldenberg DM
Bioconjug Chem; 1997; 8(4):595-604. PubMed ID: 9258460
[TBL] [Abstract][Full Text] [Related]
12. Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy.
Cardillo TM; Karacay H; Goldenberg DM; Yeldell D; Chang CH; Modrak DE; Sharkey RM; Gold DV
Clin Cancer Res; 2004 May; 10(10):3552-61. PubMed ID: 15161715
[TBL] [Abstract][Full Text] [Related]
13. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
[TBL] [Abstract][Full Text] [Related]
14. Plasma stability and pharmacokinetics of radiolabeled deferoxamine-biotin derivatives.
Rosebrough SF
J Pharmacol Exp Ther; 1993 Apr; 265(1):408-15. PubMed ID: 8474023
[TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of capsular polysaccharide-specific IgM and IgG antibodies and F(ab')2 and Fab fragments as delivery vehicles for radioimmunotherapy of fungal infection.
Dadachova E; Bryan RA; Huang X; Ortiz G; Moadel T; Casadevall A
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5629s-5635s. PubMed ID: 17875799
[TBL] [Abstract][Full Text] [Related]
16. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.
Su FM; Beaumier P; Axworthy D; Atcher R; Fritzberg A
Nucl Med Biol; 2005 Oct; 32(7):741-7. PubMed ID: 16243650
[TBL] [Abstract][Full Text] [Related]
17. Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma.
Hamblett KJ; Press OW; Meyer DL; Hamlin DK; Axworthy D; Wilbur DS; Stayton PS
Bioconjug Chem; 2005; 16(1):131-8. PubMed ID: 15656584
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
Buchsbaum DJ; Khazaeli MB; Axworthy DB; Schultz J; Chaudhuri TR; Zinn KR; Carpenter M; LoBuglio AF
Clin Cancer Res; 2005 Nov; 11(22):8180-5. PubMed ID: 16299250
[TBL] [Abstract][Full Text] [Related]
19. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
Shen S; Forero A; LoBuglio AF; Breitz H; Khazaeli MB; Fisher DR; Wang W; Meredith RF
J Nucl Med; 2005 Apr; 46(4):642-51. PubMed ID: 15809487
[TBL] [Abstract][Full Text] [Related]
20. Improving tumor-to-normal-tissue ratios of antibodies by extracorporeal immunoadsorption based on the avidin-biotin concept: development of a new treatment strategy applied to monoclonal antibodies murine L6 and chimeric BR96.
Tennvall J; Garkavij M; Chen J; Sjögren HO; Strand SE
Cancer; 1997 Dec; 80(12 Suppl):2411-8. PubMed ID: 9406691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
